Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.
1. A lipocalin mutein having binding specificity for IL-17A and comprising, at positions corresponding to positions 26-34, 55-58, 60-61, 64, 101, 104-108, 111, 114 and 153 of the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1), the same set of amino acid residues that one of the muteins set forth in SEQ ID NOs: 2-5 and 14 has at the respective positions, wherein the lipocalin mutein has at least 90% sequence identity to the amino acid sequence of one of the muteins set forth in SEQ ID NOs: 2-5 and 14.
2. The lipocalin mutein of claim 1 , wherein the lipocalin mutein has at least 95% sequence identity to the amino acid sequence of one of the muteins set forth in SEQ ID NOs: 2-5 and 14.
3. The lipocalin mutein of claim 1 , wherein the lipocalin mutein comprises, at positions corresponding to positions 26-34, 55-58, 60-61, 64, 101, 104-108, 111, 114 and 153 of the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1), the same set of amino acid residues set forth in SEQ ID NO: 2 at the respective positions.
4. The lipocalin mutein of claim 1 , wherein the lipocalin mutein comprises, at positions corresponding to positions 26-34, 55-58, 60-61, 64, 101, 104-108, 111, 114 and 153 of the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1), the same set of amino acid residues set forth in SEQ ID NO: 3 at the respective positions.
5. The lipocalin mutein of claim 1 , wherein the lipocalin mutein comprises, at positions corresponding to positions 26-34, 55-58, 60-61, 64, 101, 104-108, 111, 114 and 153 of the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1), the same set of amino acid residues set forth in SEQ ID NO: 4 at the respective positions.
6. The lipocalin mutein of claim 1 , wherein the lipocalin mutein comprises, at positions corresponding to positions 26-34, 55-58, 60-61, 64, 101, 104-108, 111, 114 and 153 of the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1), the same set of amino acid residues set forth in SEQ ID NO: 5 at the respective positions.
7. The lipocalin mutein of claim 1 , wherein the lipocalin mutein comprises, at positions corresponding to positions 26-34, 55-58, 60-61, 64, 101, 104-108, 111, 114 and 153 of the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1), the same set of amino acid residues set forth in SEQ ID NO: 14 at the respective positions.
8. The lipocalin mutein of claim 1 , wherein the lipocalin mutein comprises the polypeptide sequence of any of SEQ ID NOs: 2-5 and 14.
9. The lipocalin mutein of claim 1 , wherein the lipocalin mutein is fused at its N-terminus and/or its C-terminus to a moiety which is a protein, or a protein domain or a peptide.
10. The lipocalin mutein of claim 1 , wherein the lipocalin mutein is conjugated to a compound selected from the group consisting of an organic molecule, an enzyme label, a radioactive label, a colored label, a fluorescent label, a chromogenic label, a luminescent label, a hapten, digoxigenin, biotin, a cytostatic agent, a toxin, a metal complex, a metal, and colloidal gold.
11. The lipocalin mutein of claim 1 , wherein the lipocalin mutein is conjugated to a moiety that extends the serum half-life of the mutein, wherein the moiety that extends the serum half-life is selected from the group consisting of a polyalkylene glycol molecule, a polyethylene glycol molecule, hydroxyethyl starch, a Fc part of an immunoglobulin, a CH3 domain of an immunoglobulin, a CH4 domain of an immunoglobulin, an albumin binding peptide, and an albumin binding protein.
12. A diagnostic or analytical kit comprising the lipocalin mutein of claim 1 .
13. A nucleic acid molecule comprising a nucleotide sequence encoding the lipocalin mutein of claim 1 .
14. A host cell containing the nucleic acid molecule of claim 13 .
15. A method of producing the lipocalin mutein of claim 1 , wherein the method comprises culturing a host cell transformed with a nucleic acid encoding said lipocalin mutein under conditions suitable for expression of the nucleic acid so that the lipocalin mutein is produced.
16. A method of detecting the presence of IL-17A in a sample, the method comprising contacting the sample with the lipocalin mutein of claim 1 under conditions that allow the formation of a complex of the lipocalin mutein and IL-17A and detecting the complex for the presence of IL-17A.